Ikris Pharma
About Us Named Patient Program
Cities We Serve Contact Us

Serious Infections

Medicines for Serious Infections in India: Imported Options for Resistant and Transplant Infections

Written by Nitin Goswami Medically reviewed by Dr. Chirag C Shah Last updated
QUICK ANSWERIn Indian hospitals, the germs behind intensive-care infections often shrug off the usual strong antibiotics. A network of 26 large hospitals found carbapenem resistance in 77% of Acinetobacter and 72% of Klebsiella bloodstream infections [1], and more than one in three adults admitted to ICU with sepsis did not leave hospital alive [2]. People who have had a stem cell or organ transplant face a second risk: cytomegalovirus (CMV) waking up while their immunity is held down. A handful of newer antibiotics and antivirals for these situations are approved in the US or Europe but are rarely, if ever, found on Indian pharmacy shelves. Through Named Patient Program (NPP), the family can get 7 of them, each imported for one named patient, once the treating specialist has written the prescription.
77%
of Acinetobacter bloodstream infections in 26 Indian tertiary hospitals were resistant to carbapenems; for Klebsiella the figure was 72%
Source: Indian HAI surveillance network, Lancet Glob Health 2022 [1]
36.3%
hospital death rate among 1,172 adults with sepsis in 19 Indian ICUs, rising to 50.8% in those with septic shock
Source: SEPSIS INDIA registry, 2022–23 [2]
About 45%
of infections in ICU sepsis patients were caused by multidrug-resistant organisms, in a one-day survey of 35 Indian ICUs
Source: Sepsis in India Prevalence Study [3]
43.8%
of 130 allogeneic stem cell transplant patients at a Kolkata cancer centre had CMV reactivation; 99% carried the virus beforehand
Source: Indian J Med Microbiol 2018 [4]

Which infections this page is about

"Serious infection" can mean many things. On this page it means two groups of patients that Indian hospital doctors meet every week. The first group has a bacterial infection, usually picked up in hospital, that no longer responds to the antibiotics on the ward shelf. The second group has a weakened immune system, most often after a bone marrow (stem cell) transplant, a kidney transplant or advanced HIV, and is fighting a germ that a healthy body would keep in check.

InfectionWho is usually affectedImported medicines on this page
Pneumonia or urinary infection from resistant Gram-negative bacteria (Acinetobacter, Klebsiella, Pseudomonas, E. coli)Patients on a ventilator, in ICU, after surgery or with a urinary catheterFetcroja (cefiderocol), Xacduro (sulbactam + durlobactam)
Clostridioides difficile (C. difficile) diarrhoeaPeople who recently took antibiotics, older patients, long hospital staysDificid (fidaxomicin)
Cytomegalovirus (CMV)Stem cell and kidney transplant recipients; people with AIDS (CMV of the eye)Prevymis (letermovir), Livtencity (maribavir), Foscavir (foscarnet)
Herpes simplex that resists acyclovirPeople whose immunity is weakenedFoscavir (foscarnet)
Pneumocystis pneumonia (PCP)People with HIV and a low CD4 count, and others on strong immune-lowering treatmentPentacarinat (pentamidine)

What Indian hospital data shows

India has no single register of drug-resistant infections, but several large multi-hospital studies point the same way.

  • Resistance is the norm in ICU bloodstream infections. Between May 2017 and October 2018, 26 tertiary hospitals reported 2,622 bloodstream and 737 urinary infections caught in 89 ICUs. Klebsiella was the most frequent germ in the blood (24.8%). Carbapenems failed against 77% of Acinetobacter, 72% of Klebsiella and 64% of Pseudomonas bloodstream infections [1].
  • Sepsis remains deadly. The SEPSIS INDIA registry followed 1,172 adults across 19 ICUs from August 2022 to July 2023. About two in three positive cultures grew Gram-negative bacteria, half of the Gram-negative blood isolates were carbapenem-resistant, and the hospital death rate was 36.3% [2]. Lungs were the most common source of infection.
  • Multidrug resistance is everyday ICU work. On a single survey day in 35 Indian ICUs, 382 of 677 adults had sepsis, about 45% of their infections involved multidrug-resistant organisms, and 14.1% were fungal [3].
  • CMV is almost universal before transplant. At a Kolkata cancer centre, 99% of transplant patients and 94% of donors already carried CMV; the virus became active again in 43.8% of 130 patients, at a median of 118 days after transplant [4]. A Navi Mumbai centre saw CMV reactivation in 80.5% of unrelated-donor and half-matched (haploidentical) transplants [5].
  • C. difficile is under-tested. A review of 31 Indian studies put the share of C. difficile infection at between 3.4% and 18% of patients tested, with recent antibiotics, long admissions, surgery and acid-reducing tablets as the common risk factors [6].

Worldwide, about 1.27 million deaths in 2019 were directly caused by bacteria that resisted treatment, according to the Global Burden of Disease analysis [7].

When a specialist may ask for an imported medicine

These medicines are not first choices. Infectious disease specialists usually keep them for the moment when the culture report, the viral load or the patient's condition shows that standard treatment is not enough. The approval of each one is narrow, and the table below follows the wording of the current labels, for example those of Fetroja [8], Xacduro [9], Prevymis [10] and Livtencity [11].

What the reports showMedicine approved for it
Complicated urinary infection or hospital / ventilator pneumonia in an adult, caused by a susceptible Gram-negative germFetcroja (sold in the US as Fetroja)
Hospital or ventilator pneumonia in an adult, caused by susceptible Acinetobacter baumannii-calcoaceticus complex onlyXacduro
C. difficile diarrhoea in an adult or a child aged 6 months or moreDificid
Preventing CMV in a CMV-positive adult or child after an allogeneic stem cell transplant, or in a high-risk kidney transplant (donor positive, recipient negative)Prevymis
CMV after a transplant that has not cleared with ganciclovir, valganciclovir, cidofovir or foscarnetLivtencity
CMV retinitis in AIDS, or acyclovir-resistant skin and mucosal herpes in an immunocompromised patientFoscavir
Treating Pneumocystis pneumonia (PCP) with an injection or dripPentacarinat

Imported serious infections medicines by type

All 7 medicines below are prescription-only. Tap a type to filter. Each card opens the full medicine page with dosage, storage and safety details.

Compare all 7 serious infections medicines

MedicineGeneric nameSerious infections typeFormApproved by
FetcrojacefiderocolResistant bacteriaIV infusionEMA (Europe), US FDA (as Fetroja)
Xacdurosulbactam + durlobactamResistant bacteriaIV infusionUS FDA
DificidfidaxomicinC. difficileTabletUS FDA
PrevymisletermovirCMVTabletUS FDA, EMA (Europe)
LivtencitymaribavirCMVTabletUS FDA, EMA (Europe)
FoscavirfoscarnetCMV, Herpes (HSV)IV infusionUS FDA
Pentacarinatpentamidine isetionatePneumocystis (PCP)InjectionMHRA (UK), ANSM (France)

Reports that decide which medicine fits

ReportWhy it mattersMedicines it applies to
Culture with sensitivity (antibiogram) from blood, urine, tracheal aspirate or BALNames the germ and shows which antibiotics still work against it; both antibacterial labels limit use to susceptible isolatesFetcroja, Xacduro
Kidney function (creatinine clearance)The dose of several of these medicines changes with kidney function, and foscarnet itself can harm the kidneysFetcroja, Xacduro, Foscavir
Stool test for C. difficile toxin or toxin geneConfirms that diarrhoea is caused by C. difficile and not by another causeDificid
CMV antibody status (donor and recipient) and CMV DNA (PCR) loadAntibody status decides who needs prevention; a viral load that does not fall on treatment points to refractory CMVPrevymis, Livtencity, Foscavir
Sputum or BAL test for Pneumocystis, and CD4 count in HIVConfirms PCP and shows how weak the immune system isPentacarinat

When the need is urgent: what families can do

A patient on a ventilator cannot wait long, so it helps to start the paperwork as soon as the specialist mentions one of these names. Each import needs the patient's own application to CDSCO and a permit in the patient's name before the medicine can be shipped. Our team prepares the forms with you; the steps and documents are listed on our import permit guide.

Fetcroja and Xacduro vials have to be kept between 2 °C and 8 °C before use, so they go straight to the hospital pharmacy in a cold box with temperature records; see how hospital delivery works. Dificid, Prevymis and Livtencity tablets are stored at room temperature.

The legal basis for importing a medicine missing from the Indian market is explained on our Indian import rules page. Transplant patients often need CMV prevention for 100 days or longer, so ask early about manufacturer and charity support programs.

Why doctors keep these medicines in reserve

Every bacterium that survives an antibiotic can pass on its survival trick. For that reason the US labels of Fetroja, Xacduro and Dificid all ask doctors to use them only when there is good reason to believe bacteria (for Dificid, C. difficile) are behind the infection. Your hospital may also have an antibiotic stewardship team that reviews such requests. If your doctor says one of these medicines is not needed yet, that is usually a deliberate choice to keep it working for later.

How to get these serious infections medicines in India

1

Prescription
Your doctor prescribes the medicine.

2

Share documents
Send the prescription and latest reports through Online Order.

3

Import paperwork
Our team checks the source and the import permissions.

4

Delivery
Delivered with the right storage, including cold chain.

Read How to Order and Indian import regulations. We also serve patients in Delhi NCR, Bangalore, Chennai, Mumbai, Kolkata, Hyderabad and Pune.

Has your doctor prescribed one of these medicines?

Share the prescription and we will guide you on availability and next steps.

Online Order

Read more about serious infections

References

  1. Mathur P et al. Health-care-associated bloodstream and urinary tract infections in a network of hospitals in India: a multicentre, hospital-based, prospective surveillance study. Lancet Glob Health. 2022;10(9):e1317-e1325. https://pubmed.ncbi.nlm.nih.gov/35961355/
  2. Todi S et al. A multicentre prospective registry of one thousand sepsis patients admitted in Indian ICUs (SEPSIS INDIA) study. Crit Care. 2024;28(1):375. https://pubmed.ncbi.nlm.nih.gov/39563464/
  3. Hammond NE et al. Estimates of sepsis prevalence and outcomes in adult patients in the ICU in India: a cross-sectional study. Chest. 2022;161(6):1543-1554. https://pubmed.ncbi.nlm.nih.gov/35092747/
  4. Kumar M et al. Cytomegalovirus reactivation and disease amongst patients with allogeneic haematopoietic stem cell transplantation in Eastern India. Indian J Med Microbiol. 2018;36(1):49-53. https://pubmed.ncbi.nlm.nih.gov/29735826/
  5. Gokarn A et al. Incidence, risk factors, and outcomes of viral reactivations in alternative donor hematopoietic stem cell transplants. Blood Cell Ther. 2025;8(4):290-300. https://pubmed.ncbi.nlm.nih.gov/41368191/
  6. Ghia CJ et al. Systematic literature review on burden of Clostridioides difficile infection in India. Clin Pathol. 2021;14:2632010X211013816. https://pubmed.ncbi.nlm.nih.gov/34104883/
  7. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655. https://pubmed.ncbi.nlm.nih.gov/35065702/
  8. Fetroja (cefiderocol) US prescribing information, DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75c0c785-38e0-4049-a6fb-b77581f5b35c
  9. Xacduro (sulbactam; durlobactam) US prescribing information, DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0167aec-a89d-4e96-afe5-2ccf3e89fe72
  10. Prevymis (letermovir) US prescribing information, DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b49df80-be4f-47e0-a0b7-123f3e69395b
  11. Livtencity (maribavir) US prescribing information, DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c94fc2c5-e840-4f18-b7d8-d5eacb26d3a0

This page gives general information only and does not replace medical advice. All medicines listed are prescription-only and must be used under a qualified doctor.

Serious Infections Medicines:
Questions Patients Ask

Short answers to what patients and families ask us most.

More FAQs

Meet the NPP Assistant: ask us anything about NPP